Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.

Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, Faddegon BA, Fiedler D, Shokat K, Houseman BT, Chao R, Pieper RO, Shannon K.

Cancer Res. 2011 Jan 1;71(1):106-15. doi: 10.1158/0008-5472.CAN-10-2732.

2.

Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.

Choi G, Huang B, Pinarbasi E, Braunstein SE, Horvai AE, Kogan S, Bhatia S, Faddegon B, Nakamura JL.

Cancer Res. 2012 Dec 15;72(24):6425-34. doi: 10.1158/0008-5472.CAN-12-1728. Epub 2012 Oct 15.

3.

Therapy-induced malignant neoplasms in Nf1 mutant mice.

Chao RC, Pyzel U, Fridlyand J, Kuo YM, Teel L, Haaga J, Borowsky A, Horvai A, Kogan SC, Bonifas J, Huey B, Jacks TE, Albertson DG, Shannon KM.

Cancer Cell. 2005 Oct;8(4):337-48.

4.

Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1.

Maris JM, Wiersma SR, Mahgoub N, Thompson P, Geyer RJ, Hurwitz CG, Lange BJ, Shannon KM.

Cancer. 1997 Apr 1;79(7):1438-46.

PMID:
9083167
5.

Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo.

Ingram DA, Yang FC, Travers JB, Wenning MJ, Hiatt K, New S, Hood A, Shannon K, Williams DA, Clapp DW.

J Exp Med. 2000 Jan 3;191(1):181-8.

6.

Myeloid malignancies induced by alkylating agents in Nf1 mice.

Mahgoub N, Taylor BR, Le Beau MM, Gratiot M, Carlson KM, Atwater SK, Jacks T, Shannon KM.

Blood. 1999 Jun 1;93(11):3617-23.

7.

Monoallelic loss of the imprinted gene Grb10 promotes tumor formation in irradiated Nf1+/- mice.

Mroue R, Huang B, Braunstein S, Firestone AJ, Nakamura JL.

PLoS Genet. 2015 May 22;11(5):e1005235. doi: 10.1371/journal.pgen.1005235. eCollection 2015 May. Erratum in: PLoS Genet. 2015 Jun;11(6):e1005327.

8.

Mutational Analysis of Ionizing Radiation Induced Neoplasms.

Sherborne AL, Davidson PR, Yu K, Nakamura AO, Rashid M, Nakamura JL.

Cell Rep. 2015 Sep 22;12(11):1915-26. doi: 10.1016/j.celrep.2015.08.015. Epub 2015 Sep 3.

9.

Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.

Gottfried ON, Viskochil DH, Couldwell WT.

Neurosurg Focus. 2010 Jan;28(1):E8. doi: 10.3171/2009.11.FOCUS09221.

PMID:
20043723
10.

In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells.

Mahgoub N, Taylor BR, Gratiot M, Kohl NE, Gibbs JB, Jacks T, Shannon KM.

Blood. 1999 Oct 1;94(7):2469-76.

11.

Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment.

Rubino C, de Vathaire F, Shamsaldin A, Labbe M, LĂȘ MG.

Br J Cancer. 2003 Sep 1;89(5):840-6.

12.

Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice.

Cutts BA, Sjogren AK, Andersson KM, Wahlstrom AM, Karlsson C, Swolin B, Bergo MO.

Blood. 2009 Oct 22;114(17):3629-32. doi: 10.1182/blood-2009-02-205146. Epub 2009 Aug 26.

13.

A mild mutator phenotype arises in a mouse model for malignancies associated with neurofibromatosis type 1.

Garza R, Hudson RA 3rd, McMahan CA, Walter CA, Vogel KS.

Mutat Res. 2007 Feb 3;615(1-2):98-110.

PMID:
17208258
14.

NF1 mice: smaller brains but no tumours.

Hafezparast M.

Trends Mol Med. 2001 Jul;7(7):285. No abstract available.

PMID:
11425624
15.

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM.

Blood. 2004 Jun 1;103(11):4243-50. Epub 2004 Feb 24.

16.

Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development.

Shin J, Padmanabhan A, de Groh ED, Lee JS, Haidar S, Dahlberg S, Guo F, He S, Wolman MA, Granato M, Lawson ND, Wolfe SA, Kim SH, Solnica-Krezel L, Kanki JP, Ligon KL, Epstein JA, Look AT.

Dis Model Mech. 2012 Nov;5(6):881-94. doi: 10.1242/dmm.009779. Epub 2012 Jul 5.

17.

Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.

Stansfield BK, Bessler WK, Mali R, Mund JA, Downing BD, Kapur R, Ingram DA Jr.

Am J Pathol. 2014 Jan;184(1):79-85. doi: 10.1016/j.ajpath.2013.09.022. Epub 2013 Nov 7.

18.

Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.

Weiss B, Bollag G, Shannon K.

Am J Med Genet. 1999 Mar 26;89(1):14-22. Review.

PMID:
10469432
19.

The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.

Barkan B, Starinsky S, Friedman E, Stein R, Kloog Y.

Clin Cancer Res. 2006 Sep 15;12(18):5533-42.

PMID:
17000690
20.

Suppression of oncogenic Ras by mutant neurofibromatosis type 1 genes with single amino acid substitutions.

Nakafuku M, Nagamine M, Ohtoshi A, Tanaka K, Toh-e A, Kaziro Y.

Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6706-10.

Supplemental Content

Support Center